The CAIN Trial aims to assess the success and safety of the HistoSonics Investigational system for the treatment of primary solid renal tumours. The procedure is completely non-invasive, knifeless, and needless.
Current kidney therapies such as partial nephrectomy and thermal ablation are invasive and can potentially exhibit complications from bleeding and infection. Whereas non-invasive histotripsy avoids these and provides the potential to destroy targeted tissue without damaging non-targeted kidney tissue.
If you are interested in taking part, please contact [email protected] or [email protected]